In the last few days researchers from the Vaccine Research Center at the US NIH released a paper for peer review on the performance of a new mRNA vaccine targeting Omicron variant, delivered as a ‘booster’ after two doses of mRNA vaccine targeting the original Wuhan strain (ie, the current type of covid vaccine).
0 subscriptions will be displayed on your profile (edit)
Skip for now
For your security, we need to re-authenticate you.
Click the link we sent to , or click here to sign in.